^
    almost2years
    All else being equal, prognosis is best for 1) dMMR colorectal cancer and 2) left-sided KRAS/NRAS/BRAF wild-type without HER2 overexpression. But - prognosis is not destiny. Every situation is different. (@gabe_a_brooks)
    HER-2 (Human epidermal growth factor receptor 2) • KRAS (KRAS proto-oncogene GTPase) • BRAF (B-raf proto-oncogene) • NRAS (Neuroblastoma RAS viral oncogene homolog)
    |
    MSI-H/dMMR • HER-2 overexpression • KRAS wild-type • BRAF wild-type • NRAS wild-type
    almost2years
    Correct - upfront EGFR inhibitor is for left-sided, KRAS/NRAS/BRAF-wild type colorectal cancer without HER-2 overexpression - kind of a mouthful (@gabe_a_brooks)
    HER-2 (Human epidermal growth factor receptor 2) • KRAS (KRAS proto-oncogene GTPase) • BRAF (B-raf proto-oncogene) • NRAS (Neuroblastoma RAS viral oncogene homolog)
    |
    HER-2 overexpression • KRAS wild-type • BRAF wild-type • NRAS wild-type
    almost2years
    Multi-line therapy trial in unresectable wild-type #KRAS #NRAS #BRAF metastatic colorectal cancer A GERCOR-PRODIGE randomized open-label phase III study. Excelente presentación por MD. Benoist Chibaudel👏 #ASCO22 #Oncology @OncologyIolc @OncoAlert @ASCO (@Dr_Ivanoncologo)
    Clinical • P3 data
    |
    KRAS (KRAS proto-oncogene GTPase) • BRAF (B-raf proto-oncogene)
    |
    KRAS wild-type • NRAS wild-type
    almost2years
    STRATEGIC-1: Multi-line therapy trial in unresectable wild-type KRAS/NRAS/BRAF metastatic colorectal cancer—A GERCOR-PRODIGE randomized open-label phase III study. Talk by Dr. Benoist Chibaudel, MD #ASCO22 #CRCSM @OncoAlert (@manjuggm)
    Clinical • P3 data
    |
    KRAS (KRAS proto-oncogene GTPase) • BRAF (B-raf proto-oncogene)
    |
    KRAS wild-type • RAS wild-type • NRAS wild-type • RAS wild-type + BRAF wild-type
    almost2years
    STRATEGIC-1: Multi-line therapy trial in unresectable wild-type KRAS/NRAS/BRAF metastatic colorectal cancer—A GERCOR-PRODIGE randomized open-label phase III study. Talk by Dr. Benoist Chibaudel, MD #ASCO22 #CRCSM (@manjuggm)
    Clinical • P3 data
    |
    KRAS (KRAS proto-oncogene GTPase) • BRAF (B-raf proto-oncogene)
    |
    KRAS wild-type • RAS wild-type • NRAS wild-type • RAS wild-type + BRAF wild-type
    almost2years
    STRATEGIC-1: Multi-line therapy trial in unresectable wild-type KRAS/NRAS/BRAF metastatic colorectal cancer—A GERCOR-PRODIGE randomized open-label phase III study. Talk by Dr. Benoist Chibaudel, MD #ASCO22 #CRCSM (@manjuggm)
    Clinical • P3 data
    |
    KRAS (KRAS proto-oncogene GTPase) • BRAF (B-raf proto-oncogene)
    |
    KRAS wild-type • RAS wild-type • NRAS wild-type • RAS wild-type + BRAF wild-type
    almost2years
    STRATEGIC-1: Multi-line therapy trial in unresectable wild-type KRAS/NRAS/BRAF metastatic colorectal cancer—A GERCOR-PRODIGE randomized open-label phase III study. Talk by Dr. Benoist Chibaudel, MD #ASCO22 #CRCSM (@manjuggm)
    Clinical • P3 data
    |
    KRAS (KRAS proto-oncogene GTPase) • BRAF (B-raf proto-oncogene)
    |
    KRAS wild-type • RAS wild-type • NRAS wild-type • RAS wild-type + BRAF wild-type
    almost2years
    STRATEGIC-1: Multi-line therapy trial in unresectable wild-type KRAS/NRAS/BRAF metastatic colorectal cancer—A GERCOR-PRODIGE randomized open-label phase III study. Talk by Dr. Benoist Chibaudel, MD #ASCO22 #CRCSM (@manjuggm)
    Clinical • P3 data
    |
    KRAS (KRAS proto-oncogene GTPase) • BRAF (B-raf proto-oncogene)
    |
    KRAS wild-type • RAS wild-type • NRAS wild-type • RAS wild-type + BRAF wild-type